AI
AdvisorShares Investments Portfolio holdings
AUM
$555M
1-Year Return
19.49%
This Quarter Return
+6.68%
1 Year Return
+19.49%
3 Year Return
+67.68%
5 Year Return
+78.74%
10 Year Return
–
AUM
$522M
AUM Growth
-$52.5M
(-9.1%)
Cap. Flow
-$74.2M
Cap. Flow
% of AUM
-14.21%
Top 10 Holdings %
Top 10 Hldgs %
50.64%
Holding
316
New
43
Increased
78
Reduced
127
Closed
48
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$106M |
| 2 |
iShares Morningstar US Equity ETF
ILCB
|
$29.5M |
| 3 |
Consumers Staples Select Sector SPDR Fund
XLP
|
$5.22M |
| 4 |
AdvisorShares Pure US Cannabis ETF
MSOS
|
$4.37M |
| 5 |
Barclays
BCS
|
$642K |
Top Sells
Sector Composition
| 1 | Technology | 10.98% |
| 2 | Financials | 9.81% |
| 3 | Healthcare | 8.91% |
| 4 | Consumer Discretionary | 8.64% |
| 5 | Industrials | 5.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JMIA
201
Jumia Technologies
JMIA
$1B
| $244K | 0.05% |
+45,675
| New | +$244K |
|
202
Alkermes
ALKS
$4.77B
| $232K | 0.04% |
8,290
-3,100
| -27% | -$86.8K |
|
203
Trip.com Group
TCOM
$47.7B
| $232K | 0.04% |
3,896
| – | – |
|
204
Relmada Therapeutics
RLMD
$45.5M
| $222K | 0.04% |
68,528
-21,500
| -24% | -$69.7K |
|
205
NRX Pharmaceuticals
NRXP
$62.5M
| $220K | 0.04% |
130,085
+22,000
| +20% | +$37.2K |
|
|
DRUG
206
Bright Minds Biosciences
DRUG
$312M
| $219K | 0.04% |
182,420
+1,428
| +0.8% | +$1.71K |
|
|
INCR
207
Intercure
INCR
$85.9M
| $216K | 0.04% |
107,414
| – | – |
|
208
GH Research
GHRS
$872M
| $209K | 0.04% |
31,205
+8,600
| +38% | +$57.5K |
|
209
Clearmind Medicine
CMND
$5.49M
| $208K | 0.04% |
170,641
+42,000
| +33% | +$51.2K |
|
|
ITCI
210
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $205K | 0.04% |
2,805
-900
| -24% | -$65.9K |
|
211
Norwegian Cruise Line
NCLH
$11.6B
| $205K | 0.04% |
10,000
+1,000
| +11% | +$20.5K |
|
212
VistaGen Therapeutics
VTGN
$111M
| $204K | 0.04% |
67,780
+16,000
| +31% | +$48.2K |
|
213
Royal Caribbean
RCL
$97.8B
| $195K | 0.04% |
1,100
| – | – |
|
214
ATAI Life Sciences
ATAI
$977M
| $195K | 0.04% |
167,831
-33,000
| -16% | -$38.3K |
|
215
Enveric Biosciences
ENVB
$3.28M
| $174K | 0.03% |
24,470
+3,334
| +16% | +$23.7K |
|
216
InMed Pharmaceuticals
INM
$4.18M
| $172K | 0.03% |
+36,665
| New | +$172K |
|
217
Target Hospitality
TH
$867M
| $170K | 0.03% |
21,889
-700
| -3% | -$5.45K |
|
218
Wyndham Hotels & Resorts
WH
$6.58B
| $169K | 0.03% |
2,157
+500
| +30% | +$39.1K |
|
|
SAGE
219
DELISTED
Sage Therapeutics
SAGE
| $168K | 0.03% |
23,330
+7,300
| +46% | +$52.7K |
|
220
Yum China
YUMC
$16.4B
| $167K | 0.03% |
+3,700
| New | +$167K |
|
221
Expedia Group
EXPE
$26.8B
| $165K | 0.03% |
1,117
-400
| -26% | -$59.2K |
|
222
Cheesecake Factory
CAKE
$3.04B
| $165K | 0.03% |
+4,058
| New | +$165K |
|
|
INN
223
Summit Hotel Properties
INN
$617M
| $164K | 0.03% |
+23,900
| New | +$164K |
|
|
XHR
224
Xenia Hotels & Resorts
XHR
$1.4B
| $164K | 0.03% |
11,080
-700
| -6% | -$10.3K |
|
225
Brinker International
EAT
$7.11B
| $156K | 0.03% |
2,042
-1,089
| -35% | -$83.3K |
|